Sevabertinib

Major

Sevabertinib Clindamycin ANTIROBE Explained Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Colchicine Colcrys Explained Increased) CYP3A4/P-gp substrate with NTI exposure and an increased risk of CYP3A4/P-gp substrate with NTI-related adverse reactio... Details Sevabertinib Abemaciclib Verzenio Explained Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Acalabrutinib Calquence Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Axitinib Inlyta Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Bosutinib Bosulif Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Brigatinib Alunbrig Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Clindamycin Injection ANTIROBE Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Clindamycin Topical C/T/S® Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Clindamycin Vaginal Cleocin Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Cobimetinib Cotellic Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Cyclosporine Injection Atopica Increased) CYP3A4/P-gp substrate with NTI exposure and an increased risk of CYP3A4/P-gp substrate with NTI-related adverse reactio... Details Sevabertinib Cyclosporine Ophthalmic Cequa Increased) CYP3A4/P-gp substrate with NTI exposure and an increased risk of CYP3A4/P-gp substrate with NTI-related adverse reactio... Details Sevabertinib Dasatinib Phyrago Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Dexamethasone Injection Decadron Reduced sevabertinib exposure and reduced efficacy of sevabertinib Details Sevabertinib Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced sevabertinib exposure and reduced efficacy of sevabertinib Details Sevabertinib Dihydroergotamine Injection DHE-45® Injection Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Dihydroergotamine Nasal Spray Migranal Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Docetaxel Beizray Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Docetaxel Injection Beizray Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Dofetilide Tikosyn Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Encorafenib Braftovi Reduced sevabertinib exposure and reduced efficacy of sevabertinib Details Sevabertinib Entrectinib Rozlytrek Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Everolimus Afinitor Increased) CYP3A4/P-gp substrate with NTI exposure and an increased risk of CYP3A4/P-gp substrate with NTI-related adverse reactio... Details Sevabertinib Fentanyl Transdermal Patch Duragesic® Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Ketoconazole Topical Extina® Foam Increased sevabertinib exposure Details Sevabertinib Lefamulin Xenleta Increased sevabertinib exposure Details Sevabertinib Lenacapavir Injection Sunlenca Increased sevabertinib exposure Details Sevabertinib Lenacapavir Oral Sunlenca Increased sevabertinib exposure Details Sevabertinib Letermovir Injection Prevymis Increased sevabertinib exposure Details Sevabertinib Midostaurin Rydapt Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Mitapivat Aqvesme Reduced sevabertinib exposure and reduced efficacy of sevabertinib Details Sevabertinib Nafcillin Injection Unipen® Injection Reduced sevabertinib exposure and reduced efficacy of sevabertinib Details Sevabertinib Neratinib Nerlynx Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Sevabertinib Olaparib Lynparza Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details

Moderate

Sevabertinib Digoxin Cardoxin® Increased digoxin exposure and an increased risk of digoxin-related adverse reactions Details Sevabertinib Levothyroxine Ermeza Increased risk of hypothyroidism Details